Healthcare Industry News: extracorporeal circulatory support
News Release - May 4, 2010
Edward Hospital Adopts TandemHeart(R), Designed to Offer New Hope to Heart PatientsNAPERVILLE, Ill. & PITTSBURGH--(HSMN NewsFeed)--CardiacAssist Inc. announced today that Edward Hospital has adopted the company’s TandemHeart® System.
“TandemHeart is at the front lines of helping us treat critically ill cardiac patients,” said Timothy Larkin, M.D., an interventional cardiologist with Midwest Heart Specialists. “If TandemHeart were not available, our only option is an intra-aortic balloon pump versus transferring an unstable patient for a left ventricular assist device. TandemHeart allows us to provide an additional level of care to critically ill cardiac patients.”
FDA-cleared TandemHeart can be placed rapidly by both cardiac surgeons in an operating room and interventional cardiologists in a cath lab to provide short-term circulatory support for critically ill patients. Hemodynamic support includes a high net blood-flow rate of up to eight liters per minute in the OR or five liters per minute in the catheterization lab—more than twice the amount of other available technologies—and is fully reimbursed by Medicare.
Headquartered in Pittsburgh, privately held CardiacAssist is a growing and profitable medical technology company that develops, manufactures and markets cardiac assist devices. The Company has developed the world’s first and only proprietary platform, FDA-cleared and CE-Marked TandemHeart® — which provides a short-term extracorporeal circulatory support system for both cardiologists and cardiac surgeons.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.